Unilever to combine foods unit with McCormick in $44.8bn deal

Unilever agreed to combine its Foods business with McCormick in a $44.8B transaction where Unilever/its shareholders receive 65.0% of the combined equity (Unilever shareholders 55.1%, Unilever retaining 9.9%), McCormick shareholders 35.0%, and Unilever will receive $15.7B in cash. The deal implies EV/sales of 3.6x and EV/EBITDA of 13.8x (based on a $57.843 VWAP), targets ~$600M annual run-rate cost synergies by year three, and is expected to close by mid-2027 pending approvals. Post-separation Unilever becomes a home & personal care company with €39B revenue (FY25), plans to reduce net debt to ~2.0x EBITDA and fund €6B of share buybacks from 2026–2029; the transaction is structured as a Reverse Morris Trust intended to be tax-free for U.S. federal purposes.

Analysis

This deal reshapes competitive maps in global consumer foods: combining a pure-play seasonings business with a global consumer giant creates a clearer platform to squeeze procurement and route-to-market overlap, which should meaningfully lift gross margin on a 24–36 month view if execution is clean. The real optionality is international scale — getting McCormick into faster-growth emerging-market channels and leveraging Unilever's logistics could accelerate top-line mix shift away from mature US grocery, but that requires capital allocation discipline post-close.

Key downside pathways are integration and governance friction. SKU rationalization, dual-headquarter frictions, and potential localized antitrust / tax pushback introduce a non-trivial probability of delayed synergies; a one- to three-quarter slippage in cost saves would push realized IRR down substantially and compress near-term cash flow available for the announced buyback program.

For Unilever, the separation makes management accountability cleaner but concentrates exposure to home & personal care cyclicality and FX in euros — that could compress the multiple if macro weakens or if buybacks are deferred. A pragmatic view: event-driven upside centers on deal close and synergy delivery over 18–36 months; tail risks (deal unwinding, tax challenge, commodity shocks) can erase equity gains within weeks and would be the primary reversal mechanism.

Key Decisions for Investors

• Pair trade (primary): Long MKC equity, short UL equity sized 0.6x by market cap to isolate seasoning/regional-growth upside. Timeframe: enter now–close by mid-2027 (deal close) and hold through 2029 for synergy realization. Target: 25–40% gross upside if synergies/EM expansion occur; downside: ~20–30% if deal fails or execution stalls.
• Event-driven options (tactical): Buy MKC 18–30 month calls 10–20% OTM (allocate 2–3% portfolio). Rationale: convex payoff to successful integration and rerating; risk limited to premium, reward >3x if multiple expansion + synergies materialize.
• Protective stance on UL (risk-off): Buy 12–18 month UL puts or sell UL covered calls around announced buyback windows to hedge potential multiple compression. Timeframe: through 2027 separation and first full-year H&PC results. Expect protection cost to be justified if macro softens; hedge reduces portfolio downside by ~15–25% in adverse scenarios.
• Catalyst watch & size trim: Set alerts for regulatory filings, MKC shareholder vote, and the first quarter post-close synergy update. Reduce position by 30–50% at first concrete synergy miss or any formal tax/antitrust inquiry — those are high-information events that historically reprice deal equities quickly.